How long is Mavyret treatment?

Drugs.com

Official answer

by Drugs.com

How long you are treated with Mavyret depends upon your liver function, previous treatments, and other medical conditions you may have. Your doctor will decide the most appropriate length of time for your treatment regimen. In general, treatment can range from 8 to 16 weeks.

Mavyret (glecaprevir and pibrentasvir) is a prescription medicine used to treat adults and children 3 years of age and older with long-lasting (chronic) hepatitis C virus (HCV).

These regimens are appropriate for patients with either HCV infection alone or patients with both HCV and HIV infection. Cure rates for HCV range from 92% to 100%.

Mavyret comes as two dosage forms, oral tablets and oral pellets.

  • The tablets are a fixed combination drug product that contain glecaprevir 100 mg and pibrentasvir 40 mg in each tablet.
  • Mavyret oral pellets come in packet that contain glecaprevir 50 mg and pibrentasvir 20 mg in each packet. The oral pellets are recommended for children 3 years old to less than 12 years old OR weighing less than 45 kg.
  • Treatment-Naïve Patients

  • For patients who have never received HCV treatment, the recommended length of treatment for HCV genotypes 1-6 is 8 weeks (in patients with either no cirrhosis or compensated cirrhosis, meaning you have no symptoms of liver disease).
  • Treatment-Experienced Patients

  • For patients who have previously received HCV treatment, the duration of treatment can range from 8 to 16 weeks depending upon your HCV genotype, previous treatment regimen, your liver function and/or the presence of cirrhosis.
  • Liver or kidney transplant recipients

  • Mavyret is recommended for 12 weeks in adult and pediatric patients 3 years and older who are liver or kidney transplant recipients.
  • A 16-week treatment duration is recommended in HCV genotype 1 patients who are NS5A inhibitor-experienced without prior treatment with an NS3/4A protease inhibitor; or in genotype 3-infected patients who are PRS treatment-experienced. PRS means that the patients has had prior treatment experience with regimens containing (peg) interferon, ribavirin, and/or sofosbuvir, but no prior treatment experience with an HCV NS3/4A PI or NS5A inhibitor.
  • What is the Mavyret dose?

    Adult dose:

  • The recommended oral dosage of Mavyret is ​3 tablets ​taken at the same time once daily with food.
  • The total daily dose equals glecaprevir 300 mg and pibrentasvir 120 mg.
  • Pediatric dose in patients 12 years of age and older, OR who weigh at least 45 kg:

  • The recommended oral dosage of Mavyret is ​3 tablets ​taken at the same time once daily with food.
  • The total daily dose equals glecaprevir 300 mg and pibrentasvir 120 mg.
  • Pediatric dose in patients 3 years to less than 12 years old:

  • Dose is based on weight. See weight-based dosing recommendations here.
  • Follow the instructions for preparation and use of the Mavyret oral pellets. If you are not sure, ask your healthcare provider or pharmacist.
  • Take your Mavyret exactly as prescribed by your doctor. If you have a history of liver disease, be sure to tell your health care provider.

    This is not all the information you need to know about Mavyret (glecaprevir and pibrentasvir) for safe and effective use and does not take the place of talking to your doctor about your treatment. Review the full Mavyret information here, and discuss this information and any questions you have with your doctor or other health care provider.

    Related medical questions

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords